The main objectives of this trial are to investigate safety, tolerability, and pharmacokinetics of BI 3810477 in healthy male and female trial participants when given as multiple rising doses.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
47
BI 3810477
Placebo for BI 3810477
SGS Life Science Services - Clinical Research
Edegem, Belgium
Occurrence of any treatment-emergent adverse events assessed as drug-related by the investigator
Time frame: Up to Day 117
Area under the concentration-time curve of BI 3810477 in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)
Time frame: Up to Day 117
Maximum measured concentration of BI 3810477 in plasma at steady state (Cmax,ss)
Time frame: Up to Day 117
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.